A Phase III, Randomized, Open-Label, Active-Controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Chinese Pediatric Patients 1 to <12 Years of Age With Influenza Symptoms
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs Baloxavir-marboxil (Primary) ; Oseltamivir
- Indications Influenza virus infections; SARS-CoV-2 acute respiratory disease
- Focus Adverse reactions; Registrational
- Sponsors Roche
- 17 Jan 2025 New trial record